Thomas E. Stinchcombe MD; CSCO 2026: The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor's Global Perspective
JINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing. He is: Thomas Eldridge Stinchcombe MD, FASCO, Medical Oncologist and Member of the Thoracic Oncology Program at Duke Cancer Institute in Durham, North Carolina, in the USA. At the 2026 Annual Meeting of the Chinese Society of Clinical Oncology he talked about his plans with our reporter, Peter Goodwin.
The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor’s Global Perspective
An interview with:
Thomas Eldridge Stinchcombe MD FASCO, Editor-in-Chief, Journal of Clinical Oncology, Medical Oncologist, Member of the Thoracic Oncology Program, Duke Cancer Institute, Durham, North Carolina, USA
JINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing.
He is: Thomas Eldridge Stinchcombe MD, FASCO, Medical Oncologist and Member of the Thoracic Oncology Program at Duke Cancer Institute in Durham, North Carolina, in the USA.
At the 2026 Annual Meeting of the Chinese Society of Clinical Oncology he talked about his plans with our reporter, Peter Goodwin:
AUDIO JOURNAL OF ONCOLOGY, Thomas Eldridge Stinchcombe MD, FASCO
IN：I’m at the 2026 ……
OUT: ……Audio Journal of Oncology, I’m Peter Goodwin 8:54 secs
Thomas E. Stinchcombe Named New Editor-in-Chief of Journal of Clinical Oncology
https://oncodaily.com/career/thomas-e-stinchcombe-580007
ThomasStinchcombe CISCO 2026 A J Oncology Text
October 06, 2026
Related Episodes
Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from China
JINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer. The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways. In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin:
Jiujie Cui MD PhD, CSCO 2026: Early Findings Show KRAS-G12D Inhibitor More than Doubles Median Overall Survival in Patients with Advanced Pancreatic Cancer
JINAN, China—A highly selective drug that inhibits the predominant oncogenic driver (the KRAS-G12D mutation) in advanced pancreatic ductal adenocarcinoma, and minimizes side effects, has shown big promise for keeping patients alive and progression-free. This was in early trial results reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology. In phase 1b/2 study results, Chinese researchers reported marked improvements in outcomes that mirror the 2026 findings from the USA reported in the New England Journal of Medicine with a multi-selective RAS inhibitor. Peter Goodwin heard the latest from the study first author: medical oncologist Jiujie Cui MD PhD, from Renji Hospital at Shanghai Jiaotong University School of Medicine, in Shanghai, China.